NCT04750330View on ClinicalTrials.gov

Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection

CompletedOBSERVATIONAL
Enrollment

394

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
Covid19
Trial Locations (3)

Unknown

Regional Chest Diseases Hospital of Athens <Sotiria>, Athens

University of Florence, Florence

Centro Hospitalar de Setúbal, Setúbal

All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

lead

Maastricht University

OTHER

NCT04750330 - Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection | Biotech Hunter | Biotech Hunter